FLT3 and acute myeloid leukemia: The objective of the current study was to comprehensively profile the mutational landscape of FLT3-mutated AML in patients treated within the RATIFY trial using a high-throughput targeted sequencing (HTS) approach, and to correlate genetic patterns with clinical outcomes.